Hemangiol in infantile haemangioma: A paediatric post-marketing surveillance drug study

Floriane Socchi, Michele Bigorre, Marion Normandin, Guillaume Captier, Didier Bessis, Michel Mondain, Catherine Blanchet, Mohamed Akkari, Pascal Amedro, Arthur Gavotto, Floriane Socchi, Michele Bigorre, Marion Normandin, Guillaume Captier, Didier Bessis, Michel Mondain, Catherine Blanchet, Mohamed Akkari, Pascal Amedro, Arthur Gavotto

Abstract

Aim: Infantile haemangioma (IH) is the most common benign tumour in children. Since 2014, propranolol has become the first-choice therapy and currently Hemangiol is the only approved drug for complicated haemangioma. This post-marketing study reports the use of Hemangiol for IH in paediatric practice.

Method and results: From January 2014 to November 2018, 94 children (median age 4 [0; 21] months; 75% female) treated with Hemangiol for proliferative IH were enrolled in the study. The systematic paediatric cardiology consultation never contraindicated beta-blockers. Two Hemangiol initiation protocols were used: a conventional ambulatory 3-week titration phase protocol (n = 76, 80.9%), and a rapid initiation protocol with a 48-hour dose escalation in conventional hospitalization for severe proliferative or ulcerated IH (n = 18, 19.1%). In both protocols, the haemodynamic tolerance was good. The mean maintenance dose of Hemangiol was 2.7 ± 0.8 mg/kg/day, with a median treatment duration of 7 [1.5; 19] months. Adverse events (AEs) have been found in 25 (26,6%) patients, including 8 (8.5%) patients with serious AEs (uncontrolled bronchial hyperreactivity, n = 5; serious hypoglycaemia, n = 3). Some patients had one or more AEs, a total of 24 nonserious AEs was reported in 19 patients (sleep disturbances, n = 9; respiratory disorders, n = 5; digestive disorders, n = 6). No cardiac adverse event was reported.

Conclusion: This post-marketing surveillance drug study supports the good tolerance of Hemangiol in children with IH. A rapid initiation protocol is of interest when treatment is urgent. The pretherapeutic paediatric cardiology consultation should not be systematic but only indicated for specific patients. CLINICALTRIALS.GOV: NCT04105517.

Keywords: Hemangiol; infantile haemangioma; oral propranolol; safety.

© 2020 British Pharmacological Society.

References

REFERENCES

    1. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69(3):412-420.
    1. Anderson KR, Schoch JJ, Lohse CM, Hand JL, Davis DM, Tollefson MM. Increasing incidence of infantile hemangiomas over the past 35-years: correlation with decreasing gestational age at birth and birth weight. J Am Acad Dermatol. 2016;74(1):120-126.
    1. Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25(2):168-173.
    1. Wassef M, Blei F, Adams D, et al. Vascular anomalies classification: recommendations from the International Society for the Study of vascular anomalies. Pediatrics. 2015;136(1):e203-e214.
    1. Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics. 2012;130(2):e314-e320.
    1. Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360-367.
    1. Bauland CG, Lüning TH, Smit JM, Zeebregts CJ, Spauwen PHM. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg. 2011;127(4):1643-1648.
    1. Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. The Lancet. 2017;390(10089):85-94.
    1. Cheng CE, Friedlander SF. Infantile hemangiomas, complications and treatments. Semin Cutan Med Surg. 2016;35(3):108-116.
    1. Garzon MC, Epstein LG, Heyer GL, et al. PHACE syndrome: consensus-derived diagnosis and care recommendations. J Pediatr. 2016;178:24-33e2.
    1. Rotter A, Samorano LP, Rivitti-Machado MC, Oliveira ZNP, Gontijo B. PHACE syndrome: clinical manifestations, diagnostic criteria, and management. An Bras Dermatol. 2018;93(3):405-411.
    1. Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010;157(5):795-801e7.
    1. Girard C, Bigorre M, Guillot B, Bessis D. PELVIS syndrome. Arch Dermatol. 2006;142(7):884-888.
    1. Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1):1-28.
    1. Bennett ML, Fleischer AB, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137(9):1208-1213.
    1. Janmohamed SR, Madern GC, de Laat PCJ, Oranje AP. Educational paper: therapy of infantile haemangioma-history and current state (part II). Eur J Pediatr. 2015;174(2):259-266.
    1. Léauté-Labrèze C, De la Roque ED, Hubiche T, Boralevi F, Thambo J-B, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651.
    1. Léauté-Labrèze C, de la Roque ED, Nacka F, et al. Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants <4 months of age. Br J Dermatol. 2013;169(1):181-183.
    1. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735-746.
    1. Alexander SP, Christopoulos A, Davenport AP, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. Br J Pharmacol. 2017;174(Suppl 1):S17-S129.
    1. Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985;40(2):111-118.
    1. Arimone Y, Bidault I, Dutertre J-P, et al. Réactualisation de la méthode française d'imputabilité des effets indésirables des médicaments. Therapie. 2011;66(6):517-525.
    1. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007;150(3):291-294.
    1. Munden A, Butschek R, Tom WL, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170(4):907-913.
    1. Yang H, Hu D-L, Shu Q, Guo X-D. Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies. World J Pediatr. 2019;15(6):546-558.
    1. Baselga E, Dembowska-Baginska B, Przewratil P, et al. Efficacy of propranolol between 6 and 12 months of age in high-risk infantile hemangioma. Pediatrics. 2018;142(3):e20173866.
    1. Chang L, Gu Y, Yu Z, et al. When to stop propranolol for infantile hemangioma. Sci Rep. 2017;7:43292.
    1. Ji Y, Chen S, Xiang B, Yang Y, Qiu L. Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study. Sci Rep. 2017;7(1):1-8.
    1. Onnis G, Dreyfus I, Mazereeuw-Hautier J. Factors associated with delayed referral for infantile hemangioma necessitating propranolol. J Eur Acad Dermatol Venereol JEADV. 2018;32(9):1584-1588.
    1. Wedgeworth E, Glover M, Irvine AD, et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European propranolol in the treatment of complicated haemangiomas (PITCH) taskforce survey. Br J Dermatol. 2016;174(3):594-601.
    1. Leaute-Labreze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016;138(4):e20160353.
    1. Prey S, Voisard J-J, Delarue A, et al. Safety of propranolol therapy for severe infantile hemangioma. JAMA. 2016;315(4):413-415.
    1. Droitcourt C, Kerbrat S, Rault C, et al. Safety of oral propranolol for infantile hemangioma. Pediatrics. 2018;141(6):1-9.
    1. Ji Y, Chen S, Wang Q, et al. Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. Sci Rep. 2018;8(1):1-7.
    1. Frari LD, Léauté-Labrèze C, Guibaud L, et al. Propranolol pharmacokinetics in infants treated for infantile hemangiomas requiring systemic therapy: modeling and dosing regimen recommendations. Pharmacol Res Perspect. 2018;6(3):e00399.
    1. Takechi T, Kumokawa T, Kato R, Higuchi T, Kaneko T, Ieiri I. Population pharmacokinetics and pharmacodynamics of oral propranolol in pediatric patients with infantile hemangioma. J Clin Pharmacol. 2018;58(10):1361-1370.
    1. Martin K, Bleib F, Chamlin SL, et al. Propranolol treatment of infantile hemangiomas: anticipatory guidance for parents and caretakers. Pediatr Dermatol. 2013;30(1):155-159.
    1. Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010;146(7):775-778.
    1. Shepherd D, Adams S, Wargon O, Jaffe A. Childhood wheeze while taking propranolol for treatment of infantile hemangiomas. Pediatr Pulmonol. 2012;47(7):713-715.
    1. Petrovic J, Trifunovic B, Vukomanovic G, Topalovic M, Trajkovic G, Parezanović V. Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. J Dermatol Treat. 2017;28(6):554-558.
    1. Hengst M, Oelert M, Hoeger PH. Blood pressure monitoring during the induction and maintenance period of propranolol therapy for complicated infantile hemangiomas: a prospective study of 109 infants. Pediatr Dermatol. 2015;32(6):802-807.
    1. Raphael MF, Breugem CC, Vlasveld FAE, et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas? J Am Acad Dermatol. 2015;72(3):465-472.
    1. Xu D-P, Cao R-Y, Xue L, Sun N-N, Tong S, Wang X-K. Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients. J Oral Maxillofac Surg. 2015;73(3):430-436.
    1. Hoeger P, Harper J, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855-865.
    1. Puttgen KB, Summerer B, Schneider J, Cohen BA, Boss EF, Bauman NM. Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas. Ann Otol Rhinol Laryngol. 2013;122(9):550-554.
    1. Frongia G, Byeon J-O, Arnold R, Mehrabi A, Günther P. Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants. World J Pediatr. 2018;14(3):254-258.
    1. Erdoğan I. Cardiac evaluation in children with hemangiomas. Turk Kardiyol Dernegi Arsivi-Arch Turk Soc Cardiol. 2016;44(6):498-502.
    1. Yarbrough KB, Tollefson MM, Krol AL, Leitenberger SL, Mann JA, MacArthur CJ. Is routine electrocardiography necessary before initiation of propranolol for treatment of infantile hemangiomas? Pediatr Dermatol. 2016;33(6):615-620.
    1. Tang LY, Hing JW, Tang JY, et al. Predicting complications with pretreatment testing in infantile haemangioma treated with oral propranolol. Br J Ophthalmol. 2016;100(7):902-906.
    1. Chaturvedi K, Steinberg JS, Snyder CS. Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting. Cardiol Young. 2018;28(10):1105-1108.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren